15 completed, 3 recruiting, 3 withdrawn, 2 active not recruiting. 16 Phase 2, 14 Phase 1, 2 Phase 3, 1 Phase 4.
Follow Folotyn: new trials by email Literature Review of Folotyn trials Research Report on Folotyn
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL Pembrolizumab, Pralatrexate, Decitabine - PTCL, CTCL | Phase 1 | Active not recruiting | University of Virginia | 37 | 2022-02-02 | 2026-04-07 |
| Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL Azacytidine, Romidepsin, Belinostat - PTCL | Phase 2 | Recruiting | University of Virginia | 50 | 2021-02-19 | 2026-01-21 |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-04 | 2026-05-26 |
| Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL Romidepsin, Pralatrexate - Lymphoma, T-Cell, Peripheral | Phase 3 | Withdrawn | Jennifer Amengual | 2018-09-01 | 2018-12-19 | |
| Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma Durvalumab, Pralatrexate, Romidepsin - Lymphoma, T-Cell | Phase 1 / Phase 2 | Recruiting | University of Virginia | 148 | 2018-05-30 | 2022-03-31 |
| A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Pralatrexate - Peripheral T Cell Lymphoma, Progression, Disease | Phase 4 | Unknown | Taiwan Mundipharma Pharmaceuticals Ltd. | 22 | 2016-08-30 | 2017-05-12 |
| A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) Pralatrexate Injection - Peripheral T-Cell Lymphoma (PTCL) | Phase 1 | Completed | Acrotech Biopharma Inc. | 48 | 2015-11-10 | 2021-07-27 |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Pralatrexate, Romidepsin - Lymphoid Malignancies, Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Jennifer Amengual | 57 | 2013-09-09 | 2026-09-16 |
| Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® Folotyn, Fusilev - Non-Small Cell Lung Cancer | Phase 1 | Withdrawn | Acrotech Biopharma Inc. | 2013-04-01 | 2020-01-23 | |
| Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn Fusilev, Folotyn - Non Hodgkin's Lymphoma | Phase 1 | Withdrawn | Acrotech Biopharma Inc. | 2013-03-01 | 2020-01-23 | |
| KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) KW-0761, Pralatrexate, gemcitabine plus oxaliplatin - Adult T-cell Leukemia-Lymphoma | Phase 2 | Completed | Kyowa Kirin, Inc. | 71 | 2012-06-01 | 2024-04-25 |
| Erlotinib in Combination With Pralatrexate in Advanced Malignancies Erlotinib, Pralatrexate - Advanced Cancers, Solid Tumors | Phase 1 | Completed | M.D. Anderson Cancer Center | 72 | 2012-03-01 | 2016-07-04 |
| Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients Pralatrexate Injection - Peripheral T-cell Lymphoma | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 21 | 2011-08-01 | 2021-11-19 |
| Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma prednisone, cyclophosphamide, etoposide - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Completed | University of Nebraska | 34 | 2011-07-06 | 2023-09-22 |
| Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors pralatrexate, fluorouracil, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | University of Nebraska | 29 | 2010-09-14 | 2023-12-26 |
| Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer Laboratory Biomarker Analysis, Oxaliplatin, Pralatrexate - Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 35 | 2010-09-01 | 2017-12-13 |
| Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy pralatrexate, docetaxel, fludeoxyglucose F 18 - Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 6 | 2010-07-01 | 2016-06-01 |
| Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer Pralatrexate Injection, Vitamin B12, Folic Acid - Breast Cancer, Breast Tumors | Phase 2 | Completed | Acrotech Biopharma Inc. | 22 | 2010-03-01 | 2020-01-07 |
Showing 20 of 27. Sign in to see all of them.
Lymphoma, T-Cell (8) · Lymphoma, T-Cell, Peripheral (8) · Lymphoma (5) · Lymphoma, Large-Cell, Anaplastic (5) · Lymphoma, Non-Hodgkin (5) · Recurrence (4) · Hodgkin Disease (3) · Immunoblastic Lymphadenopathy (3) · Lymphoma, Follicular (3) · Adenocarcinoma Of Esophagus (2) · Burkitt Lymphoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Enteropathy-Associated T-Cell Lymphoma (2) · Esophageal Squamous Cell Carcinoma (2) · Lymphoma, B-Cell (2)
Acrotech Biopharma Inc. (8) · Spectrum Pharmaceuticals, Inc (4) · University of Virginia (3) · City of Hope Medical Center (2) · Jennifer Amengual (2) · University of Nebraska (2) · Fred Hutchinson Cancer Center (1) · Kyowa Kirin, Inc. (1) · M.D. Anderson Cancer Center (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · Taiwan Mundipharma Pharmaceuticals Ltd. (1)
United States (23) · France (5) · Belgium (4) · Italy (3) · United Kingdom (3) · Argentina (2) · Brazil (2) · Canada (2) · Czechia (2) · Hungary (2) · Spain (2) · Australia (1) · Croatia (1) · India (1) · Ireland (1)
Garry Weems, PharmD (2) · Owen O'Connor, MD, PhD (2) · Ahmed Sawas, MD (1) · Alex F Herrera (1) · Bor-Sheng Ko, PhD (1) · Christina Poh (1) · Craig Portell, MD (1) · Enrica Marchi, M.D., PhD (1) · Enrica Marchi, MD, PhD (1) · Erard Gilles, MD (1) · Garry Weems, Pharm.D. (1) · Jean Grem (1) · Jennifer Amengual, MD (1) · Jennifer E Amengual, MD (1) · Julie M Vose (1)
PMID 19652067, PMID 26242208, PMID 29141948, PMID 38029357, PMID 38517235, PMID 40932107
2008 (1), P30CA016056 (1), P30CA033572 (1), P30CA036727 (1)